|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.2000 - 0.2000|
|52 Week Range||0.0500 - 0.2000|
|Beta (5Y Monthly)||0.54|
|PE Ratio (TTM)||25.00|
|Forward Dividend & Yield||0.00 (0.97%)|
|Ex-Dividend Date||Sep 29, 2020|
|1y Target Est||N/A|
Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; Hong Kong Stock Exchange stock code: 0460) is pleased to announce that Meiyen Laboratory Inc, an American subsidiary of the Group, has entered into a strategic cooperation with the American company Genesis Biosystems recently, and obtained the exclusive distribution right for its LipiVage® fat collection system in Greater China (mainland Ch
Sihuan Pharmaceutical Holdings Group Ltd. plays a pivotal role in China's domestic medical industry and is a leading company for the development of the country's cardio-cerebral vascular prescription drugs. According to IMS data in 2018, Sihuan Pharmaceutical held a prominent place in China's national hospital prescription central cerebrovascular drug market with a share of nearly 8.3%.
Sihuan Pharmaceutical Holdings Group Ltd. plays a pivotal role in the domestic medical industry. It is a leading company in China's CCV prescription drugs. According to IMS data in 2018, Sihuan Pharmaceutical is well-known on the national hospital prescription drug market share list, with its central cerebrovascular drug market share of nearly 8.3%.